China-based WuXi STA, a subsidiary of WuXi AppTec, and Coherent Biopharma, have announced the signing of a strategic partnership agreement.

According to the agreement, WuXi STA will become the preferred contract development and manufacturing organization (CDMO) partner and provide Coherent Biopharma with integrated Chemistry, Manufacturing and Controls (CMC) services to accelerate its present and future drug candidates (small molecule, peptide, oligonucleotide and complex chemical conjugate, etc.), from API to drug product, including but not limited to the process development, manufacturing, analytical and regulatory filing support.

Coherent Biopharma has developed a diverse product pipeline with the Peptide Drug Conjugate (PDC) products, including CBP-1008 and CBP-1018, the two PDC drugs are both in clinical trials in the United States and China. Meanwhile, multiple new drugs are in various R&D stages, ready for clinical development in a few years.

Based on the prior successful collaboration on CBP-1008, this strategic partnership between Coherent Biopharma and WuXi STA is to broaden the collaboration beyond CBP-1008.